Key Takeaways
- Combination therapy of tobevibart and elebsiran achieved an 88% undetectable HDV RNA rate in chronic hepatitis delta patients after 96 weeks.
- Phase 1 data for VIR-5500, a PSMA-targeted T-cell engager in prostate cancer, will be presented at the 2026 ASCO Genitourinary Cancers Symposium.
- Vir Biotechnology reported a year-end balance of $781 million, with funds projected to last until Q4 2027.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced promising results from its Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD). The combination therapy using tobevibart, a monoclonal antibody, and elebsiran, a small interfering RNA, showed significant efficacy, achieving an undetectable hepatitis delta virus (HDV) RNA rate of 88% in evaluable participants after 96 weeks of treatment. This result builds on previous findings that indicated a 77% rate at Week 72. The combination also exhibited good tolerability, with no severe treatment-related adverse events recorded. Further results from the trial will be shared at upcoming medical conferences.
Additionally, Vir Biotechnology will present new Phase 1 data on its investigational PSMA-targeted dual-masked T-cell engager, VIR-5500, at the 2026 ASCO Genitourinary Cancers Symposium in February. This therapy is being evaluated for metastatic castration-resistant prostate cancer and has already shown potential in preliminary trials.
CEO Marianne De Backer emphasized the company’s commitment to advancing its clinical programs in 2026, forecasting significant progress in both CHD and oncology therapies. The SOLSTICE trial’s results could shift the treatment paradigm for CHD, particularly given the lack of approved therapies in the U.S. and limited options elsewhere.
Vir Biotechnology also has financial stability, reporting approximately $781 million in cash and investments at the end of 2025, thanks in part to a licensing agreement with Norgine Pharma. This financial buffer is expected to support operations well into the fourth quarter of 2027.
Looking ahead, the registrational ECLIPSE program, which assesses tobevibart in CHD, is fully enrolled. Initial data from one of its trials is anticipated in late 2026.
In addition to its hepatitis treatments, Vir Biotechnology is exploring other immunotherapies targeting solid tumors, leveraging its innovative PRO-XTEN® masking technology. This platform aims to enhance the efficacy and reduce the toxicity of T-cell engagers by activating them specifically in the tumor microenvironment.
Both the promising early data in its clinical programs and the company’s strong financial position suggest that Vir Biotechnology is well-positioned to make significant strides in addressing serious infections and cancers in the coming years.
The content above is a summary. For more details, see the source article.